UBS initiated coverage of Celldex (CLDX) with a Buy rating and $44 price target The firm says KIT inhibition is “differentiated in the underpenetrated” chronic spontaneous urticaria space. UBS sees a $3.8B market opportunity in CSU.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Buy Recommendation for Celldex: Barzolvolimab’s Market Leadership and Efficacy Drive Positive Outlook
- Blueprint Medicines price target lowered to $124 from $135 at Wedbush
- Jasper Therapeutics price target lowered to $64 from $90 at BTIG
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Jasper BEACON data ‘net positive,’ says BMO Capital